References
2. Nicola M, Alsafi Z, Sohrabi C, Kerwan A, Al-Jabir A, Iosifidis C, et al. The socio-economic implications of the coronavirus pandemic (COVID-19): A review. Int J Surg. 2020;78:185.
https://doi.org/10.1016/j.ijsu.2020.04.0187. London School of Hygiene & Tropical Medicine. One in five people globally could be at increased risk of severe COVID-19 disease through underlying health conditions [Internet]. 2020. [cited 23 Dec 2020].
8. Mikolai J, Keenan K, Kulu H. Household level health and socio-economic vulnerabilities and the COVID-19 crisis: An analysis from the UK. Epub ahead of print 2 May 2020.
https://doi.org/10.31235/osf.io/4wtz8 12. Flaxman S, Mishra S, Gandy A, Unwin HJT, Mellan TA, Coupland H, et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature. 2020;584(7820):257–61.
https://doi.org/10.1038/s41586-020-2405-7.
20. Chandan JS, Taylor J, Bradbury-Jones C, Nirantharakumar K, Kane E, Bandyopadhyay S. COVID-19: a public health approach to manage domestic violence is needed. Lancet Public Heal [Internet]. 2020 Jun 1;5(6):e309. https://doi.org/10.1016/S2468-2667(20)30112-2
26. Yu H, Sun B, Fang Z, Zhao J, Liu X, Li Y, et al. Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients. Eur Respir J [Internet]. 2020;56(6):2001526.
https://doi.org/10.1183/13993003.01526-2020 27. Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S, et al. Antibody tests for identification of current and past infection with SARS‐CoV‐2. Cochrane Database Syst Rev. 2020;(6).
https://doi.org/10.1002/14651858.CD013652 29. Van Caeseele P, Bailey D, Forgie SE, et al. SARS-CoV-2 (COVID-19) serology: implications for clinical practice, laboratory medicine and public health. Can Med Assoc J [Internet]. 2020;192(34):E973 LP-E979.
https://doi.org/10.1503/cmaj.20158830. To KK-W, Hung IF-N, Ip JD, Chu AW-H, Chan W-M, Tam AR, et al. Coronavirus Disease 2019 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing. Clin Infect Dis [Internet]. 2020 Aug 25:ciaa1275.
https://doi.org/10.1093/cid/ciaa127531. Lei Q, Li Y, Hou H-Y, Wang F, Ouyang Z-Q, Zhang Y, et al. Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections. Allergy [Internet]. 2020 Oct 10:all.14622.
https://doi.org/10.1111/all.14622 32. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan. Euro Surveill. 2020;25(10):pii=2000180.
https://doi.org/10.2807/1560-7917.ES.2020.25.10.2000180 33. Byambasuren O, Cardona M, Bell K, Clark J, McLaws M-L, Glasziou P. Estimating the extent of true asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis. medRxiv. 2020.
https://doi.org/10.1101/2020.05.10.20097543.
34. Spicuzza L, Montineri A, Manuele R, Crimi C, Pistorio MP, Campisi R, et al. Reliability and usefulness of a rapid IgM-IgG antibody test for the diagnosis of SARS-CoV-2 infection: A preliminary report. J Infect [Internet]. 2020;81(2):e53–54.
https://doi.org/10.1016/j.jinf.2020.04.02235. Peeling RW, Wedderburn CJ, Garcia PJ, Boeras D, Fongwen N, Nkengasong J, et al. Serology testing in the COVID-19 pandemic response. Lancet Infect Dis [Internet]. 2020;20(9):e245–49.
https://doi.org/10.1016/S1473-3099(20)30517-X 38. European Commission. Current performance of COVID-19 test methods and devices and proposed performance criteria - Working document of Commission services – 6 April 2020 [Report]. European Commission; 2020 p. 1-30.
https://ec.europa.eu/docsroom/documents/40805